Navigation Links
Valeant Pharmaceuticals Announces Private Exchange Offer
Date:3/29/2013

MONTREAL, March 29, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary Valeant Pharmaceuticals International (the "Company") intends to commence an offer to exchange (the "Exchange Offer") any and all of its outstanding $500 million aggregate principal amount of 6.375% Senior Notes due 2020 (the "Existing Notes") for up to an additional $500 million aggregate principal amount of its 6.375% Senior Notes due 2020 (the "Exchange Notes") issued pursuant to the indenture, dated as of October 4, 2012 (the "Date of Issuance"), as supplemented, among the Company, Valeant Pharmaceuticals International, Inc. (the "Parent"), the guarantors named therein and The Bank of New York Mellon Trust Company, as trustee.

The Exchange Notes will be guaranteed by same guarantors of the Existing Notes, which are the Parent and each of the Parent's subsidiaries (other than the Company) that is a guarantor of the Parent's senior secured credit facilities. The form and terms of the Exchange Notes will be substantially identical to the form and terms of the Existing Notes.  The Company is conducting this Exchange Offer in order to satisfy its obligations under the indenture governing the Existing Notes with the anticipated result being that some or all of such notes will be part of a single series of notes under one indenture using a single CUSIP number.

Upon the terms and subject to the conditions of the Exchange Offer, for each $1,000 principal amount of Existing Notes validly tendered, and not withdrawn, in the Exchange Offer for the Existing Notes, eligible holders will receive $1,000 principal amount of Exchange Notes.

The Exchange Offer will expire at 5:00 p.m., New York City time, on April 26, 2013, unless extended or earlier terminated by t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... Nov. 25, 2014  Array BioPharma Inc. ... that its Chief Executive Officer, Ron ... upcoming conferences.  The public is welcome to ... the Array BioPharma website:  www.arraybiopharma.com .Event: Piper ... p.m.  Eastern Time Location: Palace Hotel, New ...
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... , June 4 Amgen executive Alan ... of BeneChill, a privately held medical device company launching its ... response teams in the field, later this year in ... the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger ...
... BURLINGTON, Vt ., June 4 Mach 7 ... solutions, has relocated its global headquarters from suburban Chicago ... as the company,s base for Americas, sales and professional service operations, ... management and strategic R&D functions. , ...
Cached Medicine Technology:Veteran International Health Care Executive Appointed CEO of BeneChill(R) 2Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... 2014 Senior Planning Services, providing “expert ... nonprofit organization providing the adult demographic education and ... seniors navigate the rough seas of applying for Medicaid. ... on the topic of Medicaid eligibility and proper planning, ... of applying for this coverage. , Senior Planning ...
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... 26, 2014 Louisiana Back Institute, ... specialists in minimally invasive spine surgery, announces today ... the rapidly growing provider network of orthopedic spine ... coincides with the network’s continuing success providing the ... Louisiana residents who are suffering from orthopedic spine ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... with endometriosis may one day lead to new ways ... research suggests. What's more, the researchers may have also ... consequence of the condition. ,Anywhere from 10 to 15 ... when the tissue //that lines the uterus, the endometrium, ...
... take the newer, lower-dose birth control pills are not increasing ... birth control pills debuted in the 1960s, doctors have worried ... studies looking at the link, however, have looked at women ... levels of estrogen compared to those in use today. Whether ...
... may have solved the mystery of why dengue fever, unlike ... Dengue is a debilitating, sometimes fatal illness endemic to much ... by high fever, bone and muscle pain and -- in ... ,Dengue is also unusual in that //symptoms are more severe ...
... aren’t beneficial in the prevention of heart disease or ... speculated antioxidant vitamins, such as beta carotene (a form ... role in helping people avoid cardiovascular disease. The vitamins ... of dangerous plaque. Several preclinical studies show supplementing //the ...
... experienced a significant reduction in blood pressure as ... according to a new study. ,To investigate the ... the rest-activity cycle, Ramon C. Hermida, Ph.D., of ... Universitario, Spain, and colleagues studied a group of ...
... high cholesterol levels are more likely to develop high ... eating habits and cholesterol levels of nearly 450 preschool ... by doctors and had their HDL, or good cholesterol, ... the study show children with the highest levels of ...
Cached Medicine News:Health News:Scientists crack dengue fever puzzle 2Health News:Night Time Aspirin Regimen Found to Reduce Blood Pressure 2
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Uvex Patriot Frame...
... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...
... Radiation Protection Goggles ... can be used by ... mm leaded glass, 1.0 ... shields provide increased scatter ...
Medicine Products: